Mitochondrial homeostasis in heart failure with preserved ejection fraction: from metabolic remodeling to multi-organ crosstalk

Abstract

Heart failure with preserved ejection fraction (HFpEF) represents a predominant heart failure phenotype characterized by intricate pathophysiology and an escalating global prevalence. Beyond classical hemodynamic disturbances, emerging evidence identifies mitochondrial dysfunction as a central mechanism in HFpEF pathogenesis. This review synthesizes the pivotal mitochondrial aberrations driving HFpEF, including impaired bioenergetics, disrupted mitochondrial quality control, oxidative stress, and Ca²⁺ dyshomeostasis, particularly under the burden of cardiometabolic stressors. Importantly, we highlight that HFpEF represents a multisystem disorder wherein the mitochondria of adipose tissue, the vasculature, the immune system, and skeletal muscle actively contribute to the pathological process. By reclassifying HFpEF as a bioenergetic failure, we hope to provide a conceptual framework for the development of integrated, mitochondria-targeted therapeutic strategies.

Keywords

HFpEF / mitochondrial homeostasis / metabolic remodeling / oxidative stress / Ca²⁺ homeostasis / multi-organ crosstalk

References

[1] Cho DH.Current prevalence, incidence, and outcomes of heart failure with preserved ejection fraction.Heart Fail Clin2021;17:315-26

[2] Borlaug BA.Evaluation and management of heart failure with preserved ejection fraction.Nat Rev Cardiol2020;17:559-73

[3] Gharagozloo K,Heckman G.Heart failure with preserved ejection fraction in the elderly population: basic mechanisms and clinical considerations.Can J Cardiol2024;40:1424-44

[4] Dunlay SM,Redfield MM.Epidemiology of heart failure with preserved ejection fraction.Nat Rev Cardiol2017;14:591-602

[5] Campbell P,Lee MM,Petrie MC.Heart failure with preserved ejection fraction: everything the clinician needs to know.Lancet2024;403:1083-92

[6] Omote K,Borlaug BA.Heart failure with preserved ejection fraction: mechanisms and treatment strategies.Annu Rev Med2022;73:321-37 PMCID:PMC9002335

[7] Kumar AA,Chirinos JA.Mitochondrial dysfunction in heart failure with preserved ejection fraction.Circulation2019;139:1435-50 PMCID:PMC6414077

[8] Abudureyimu M,Wang X.Heart failure with preserved ejection fraction (HFpEF) in type 2 diabetes mellitus: from pathophysiology to therapeutics.J Mol Cell Biol2022;14 PMCID:PMC9465638

[9] Pieske B,de Boer RA.How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC).Eur Heart J2019;40:3297-317

[10] Chaanine AH,Stulak JM.Mitochondrial morphology, dynamics, and function in human pressure overload or ischemic heart disease with preserved or reduced ejection fraction.Circ Heart Fail2019;12:e005131

[11] De Jong KA.Complex energy metabolic changes in heart failure with preserved ejection fraction and heart failure with reduced ejection fraction.Can J Cardiol2017;33:860-71

[12] Ferro F,Valente C.Understanding how heart metabolic derangement shows differential stage specificity for heart failure with preserved and reduced ejection fraction.Biomolecules2022;12:969 PMCID:PMC9312956

[13] Leri AS,Zacheo A.Ablation of telomerase and telomere loss leads to cardiac dilatation and heart failure associated with p53 upregulation.EMBO J2003;22:131-9 PMCID:PMC140062

[14] Zhang A,Chang ACY.Leukocyte telomere length and risk of heart failure with preserved ejection fraction in high-risk Chinese patients with hypertension under 65 years.Geroscience2025;

[15] Chen X,Xiong W.p53-dependent mitochondrial compensation in heart failure with preserved ejection fraction.J Am Heart Assoc2022;11:e024582

[16] Li X,Zheng S.Differential mRNA Expression and circular RNA-based competitive endogenous RNA networks in the three stages of heart failure in transverse aortic constriction mice.Front Physiol2022;13:777284 PMCID:PMC8940230

[17] Guo Y,He A.iNOS contributes to heart failure with preserved ejection fraction through mitochondrial dysfunction and Akt S-nitrosylation.J Adv Res2023;43:175-86 PMCID:PMC9811328

[18] LaPenna KB,Doiron JE.Combination sodium nitrite and hydralazine therapy attenuates heart failure with preserved ejection fraction severity in a “2-Hit” murine model.J Am Heart Assoc2023;12:e028480

[19] Slotabec L,Seale B,Filho F.Cardiac diastolic dysfunction by cigarette smoking is associated with mitochondrial integrity in the heart.FASEB J2024;38:e23826 PMCID:PMC11323130

[20] Ren J,Whaley-Connell A.Mitochondrial biogenesis in the metabolic syndrome and cardiovascular disease.J Mol Med2010;88:993-1001 PMCID:PMC4319704

[21] Vázquez-Abuín X,Aragón-Herrera A.Soluble guanylate cyclase stimulation improves cardiac function and mitochondrial activity in a rat model of early-stage heart failure with preserved ejection fraction.Biomed Pharmacother2025;191:118439

[22] Müller M,Welke C.Nitro-oleic acid enhances mitochondrial metabolism and ameliorates heart failure with preserved ejection fraction in mice.Nat Commun2025;16:3933 PMCID:PMC12033319

[23] Hu Y,Zhao Q.Berberine improves cardiac insufficiency through AMPK/PGC-1α signaling-mediated mitochondrial homeostasis and apoptosis in HFpEF mice.Int Immunopharmacol2025;155:114613

[24] Inácio JM,Pinheiro M.Myocardial RNA sequencing reveals new potential therapeutic targets in heart failure with preserved ejection fraction.Biomedicines2023;11:2131 PMCID:PMC10452106

[25] Gibb AA,Eaton DM.Molecular signature of HFpEF: systems biology in a cardiac-centric large animal model.JACC Basic Transl Sci2021;6:650-72 PMCID:PMC8385567

[26] Hahn VS,Luo X.Myocardial gene expression signatures in human heart failure with preserved ejection fraction.Circulation2021;143:120-34

[27] Cao Y,Wang YC.Sex differences in heart mitochondria regulate diastolic dysfunction.Nat Commun2022;13:3850 PMCID:PMC9253085

[28] Meddeb M,Binek A.Myocardial ultrastructure of human heart failure with preserved ejection fraction.Nat Cardiovasc Res2024;3:907-14 PMCID:PMC11498130

[29] Abudureyimu M,Jiang L.FBXL4 protects against HFpEF through Drp1-Mediated regulation of mitochondrial dynamics and the downstream SERCA2a.Redox Biol2024;70:103081 PMCID:PMC10878117

[30] Shou J.PINK1 Phosphorylates Drp1(S616) to improve mitochondrial fission and inhibit the progression of hypertension-induced HFpEF.Int J Mol Sci2022;23:11934 PMCID:PMC9570161

[31] Wu D,Li H,Wang P.Drp1 knockdown aggravates obesity-induced cardiac dysfunction and remodeling.Mitochondrion2025;83:102023 PMCID:PMC12065651

[32] Wang M,Wu X.S100A9 inhibition ameliorates HFpEF by modulating mitochondrial fission and oxidative stress.Int Immunopharmacol2025;163:115280

[33] Dou Z,Huang Q.Genistein improves heart failure with preserved ejection fraction through BNIP3L-mediated mitophagy.Biochem Pharmacol2026;245:117680

[34] Zhang H,Mei X.PINK1 modulates Prdx2 to reduce lipotoxicity-induced apoptosis and attenuate cardiac dysfunction in heart failure mice with a preserved ejection fraction.Clin Transl Med2025;15:e70166

[35] Bu X,Zhang Z.Thrombospondin 1 aggravates cardiac remodeling in heart failure with preserved ejection fraction by inhibiting mitophagy.iScience2026;29:114639 PMCID:PMC12857411

[36] Miura S,Sekine T.Detyrosinated α-tubulin mediates mitochondrial dysfunction and diastolic impairment in heart failure with preserved ejection fraction.FEBS Lett2025;599:2474-90

[37] Yoshii A,Wang Y.Blunted cardiac mitophagy in response to metabolic stress contributes to HFpEF.Circ Res2024;135:1004-17 PMCID:PMC11502249

[38] Lozhkin A,Ramos-Mondragón R.Mitochondrial oxidative stress contributes to diastolic dysfunction through impaired mitochondrial dynamics.Redox Biol2022;57:102474 PMCID:PMC9530618

[39] Vujic A,Bidault G.Loss of RET-ROS at complex I induces diastolic dysfunction in mice that is reversed by aerobic exercise.Am J Physiol Heart Circ Physiol2025;329:H154-68 PMCID:PMC7617742

[40] Pepin ME,Nazir S.Mitochondrial NNT promotes diastolic dysfunction in cardiometabolic HFpEF.Circ Res2025;136:1564-78

[41] Wu T,Chu A,Niu X.PM2.5-induced programmed myocardial cell death via mPTP opening results in deteriorated cardiac function in HFpEF mice.Cardiovasc Toxicol2022;22:746-62

[42] Miranda-Silva D,Conceição G.Disturbed cardiac mitochondrial and cytosolic calcium handling in a metabolic risk-related rat model of heart failure with preserved ejection fraction.Acta Physiol2020;228:e13378

[43] Bode D,Wakula P.Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF.Cardiovasc Diabetol2021;20:7 PMCID:PMC7792219

[44] Li X,Dai X.TRPC6 deficiency attenuates mitochondrial and cardiac dysfunction in heart failure with preserved ejection fraction induced by high-fat diet plus L-NAME.Int J Mol Sci2025;26:9383 PMCID:PMC12524895

[45] Li Z,Wang Y.Renal denervation attenuates cardiac dysfunction in HFpEF by inhibiting the ATP-P2X7-NLRP3 inflammasome axis.Basic Res Cardiol2025;120:1225-47 PMCID:PMC12680762

[46] Chaanine AH,Gamb SI.FOXO3a regulates BNIP3 and modulates mitochondrial calcium, dynamics, and function in cardiac stress.Am J Physiol Heart Circ Physiol2016;311:H1540-59 PMCID:PMC5206339

[47] Zhang LL,Tang RJ.Levosimendan reverses cardiac malfunction and cardiomyocyte ferroptosis during heart failure with preserved ejection fraction via connexin 43 signaling activation.Cardiovasc Drugs Ther2024;38:705-18

[48] Ma S,He LL.Canagliflozin ameliorates ferritinophagy in HFpEF rats.J Geriatr Cardiol2025;22:178-89 PMCID:PMC11937831

[49] Paulus WJ.A novel paradigm for heart failure with preserved ejection fraction: comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation.J Am Coll Cardiol2013;62:263-71

[50] Sun Q,Wagg CS.Mitochondrial fatty acid oxidation is the major source of cardiac adenosine triphosphate production in heart failure with preserved ejection fraction.Cardiovasc Res2024;120:360-71

[51] Koleini N,Zhao L.Landscape of glycolytic metabolites and their regulating proteins in myocardium from human heart failure with preserved ejection fraction.Eur J Heart Fail2024;26:1941-51 PMCID:PMC11563863

[52] Fillmore N,Fukushima A.Uncoupling of glycolysis from glucose oxidation accompanies the development of heart failure with preserved ejection fraction.Mol Med2018;24:3 PMCID:PMC6016884

[53] Thapa D,Mushala BAS.GCN5L1 impairs diastolic function in mice exposed to a high fat diet by restricting cardiac pyruvate oxidation.Physiol Rep2022;10:e15415

[54] Zhang W,Yao W.Morphometric, hemodynamic, and multi-omics analyses in heart failure rats with preserved ejection fraction.Int J Mol Sci2020;21:3362 PMCID:PMC7247709

[55] Wang Y,Zhu J.Pyruvate metabolism enzyme Dlat induces mitochondria protein hyperacetylation to limit fatty acid oxidation in the HFpEF heart.Nat Commun2026;17 PMCID:PMC13128832

[56] Liu X,Deng Y.Mitochondrial protein hyperacetylation underpins heart failure with preserved ejection fraction in mice.J Mol Cell Cardiol2022;165:76-85

[57] Da Dalt L,Baragetti A.PCSK9 deficiency rewires heart metabolism and drives heart failure with preserved ejection fraction.Eur Heart J2021;42:3078-90 PMCID:PMC8380058

[58] Gibb AA,Gaspar RB.Integrated systems biology identifies disruptions in mitochondrial function and metabolism as key contributors to HFpEF.JACC Basic Transl Sci2025;10:101334 PMCID:PMC12390939

[59] Jani VP,Binek A.Myocardial proteome in human heart failure with preserved ejection fraction.J Am Heart Assoc2025;14:e038945 PMCID:PMC12132713

[60] Yousefi K,Takeuchi LM.Osteopontin promotes left ventricular diastolic dysfunction through a mitochondrial pathway.J Am Coll Cardiol2019;73:2705-18 PMCID:PMC6546303

[61] Caravia XM,Oliver E.The microRNA-29/PGC1α regulatory axis is critical for metabolic control of cardiac function.PLoS Biol2018;16:e2006247 PMCID:PMC6211751

[62] Ranjbarvaziri S,Wu I.Targeting HDAC6 to treat heart failure with preserved ejection fraction in mice.Nat Commun2024;15:1352

[63] Alves PKN,Augstein A.Leucine supplementation improves diastolic function in HFpEF by HDAC4 inhibition.Cells2023;12:2561 PMCID:PMC10648219

[64] Tatekoshi Y,Shapiro JS.Protein O-GlcNAcylation and hexokinase mitochondrial dissociation drive heart failure with preserved ejection fraction.Cell Metab2025;37:1584-1600.e10 PMCID:PMC12221816

[65] Schauer A,Kämmerer S.Empagliflozin improves diastolic function in HFpEF by restabilizing the mitochondrial respiratory chain.Circ Heart Fail2024;17:e011107 PMCID:PMC11177604

[66] Xu G,Sun P.Lysophosphatidylethanolamine improves diastolic dysfunction by alleviating mitochondrial injury in the aging heart.J Lipid Res2025;66:100713 PMCID:PMC11719853

[67] Herwig M,Kovács A.Diabetes mellitus aggravates myocardial inflammation and oxidative stress in aortic stenosis: a mechanistic link to HFpEF features.Cardiovasc Diabetol2025;24:203 PMCID:PMC12070770

[68] McCandless MG,Booz GW.What role do mitochondria have in diastolic dysfunction? Implications for diabetic cardiomyopathy and heart failure with preserved ejection function.J Cardiovasc Pharmacol2022;79:399-406

[69] MacIver DH.Is remodeling the dominant compensatory mechanism in both chronic heart failure with preserved and reduced left ventricular ejection fraction?.Basic Res Cardiol2010;105:227-34

[70] Morris DA,Belyavskiy E.Left ventricular longitudinal systolic function analysed by 2D speckle-tracking echocardiography in heart failure with preserved ejection fraction: a meta-analysis.Open Heart2017;4:e000630 PMCID:PMC5623331

[71] You H,Diao J.Integrative transcriptomic and single-cell analysis reveals mitochondrial-related gene biomarkers in heart failure with preserved ejection fraction.Sci Rep2025;15:44241 PMCID:PMC12722764

[72] Yoshihisa A,Yokokawa T.Associations between acylcarnitine to free carnitine ratio and adverse prognosis in heart failure patients with reduced or preserved ejection fraction.ESC Heart Fail2017;4:360-4

[73] Anguita E,Candel FJ.Biomarkers of stable and decompensated phases of heart failure with preserved ejection fraction.Int J Cardiol2022;361:91-100

[74] Ji H,Tan Z.Adipocyte extracellular vesicle mitochondrial cargo is linked to cardiomyocyte dysfunction in type 2 diabetes-related heart failure with preserved ejection fraction.Free Radic Biol Med2026;244:435-51

[75] Pan G,Yeboah EO.Targeted overexpression of mitochondrial ALDH2 in coronary endothelial cells mitigates HFpEF in a diabetic mouse model.Biomolecules2025;15:1029 PMCID:PMC12293769

[76] Otto M,Müller M.Development of heart failure with preserved ejection fraction in type 2 diabetic mice is ameliorated by preserving vascular function.Life Sci2021;284:119925 PMCID:PMC8484044

[77] Kneuer JM,Erbe S.Circulating immune cell signature analysis in HFpEF across species.Circ Res2025;137:682-98 PMCID:PMC12352558

[78] Liu H,Zhao Y.Inflammatory macrophage interleukin-1β mediates high-fat diet-induced heart failure with preserved ejection fraction.JACC Basic Transl Sci2023;8:174-85

[79] Raman J,Caluwé E.CCR2⁺ monocyte-derived macrophages drive cardiac hypertrophy in early HFpEF.Am J Physiol Heart Circ Physiol2025;329:H109-23

[80] Filipp M,DeBerge M.Myeloid fatty acid metabolism activates neighboring hematopoietic stem cells to promote heart failure with preserved ejection fraction.Circulation2025;151:1451-66 PMCID:PMC12088907

[81] Adams V,Mangner N.Ubiquitin-proteasome-system and enzymes of energy metabolism in skeletal muscle of patients with HFpEF and HFrEF.ESC Heart Fail2021;8:2556-68 PMCID:PMC8318515

[82] Vahle B,Augstein A.MyoMed205 counteracts titin hyperphosphorylation and the expression of contraction-regulating proteins in a rat model of HFpEF.J Cachexia Sarcopenia Muscle2025;16:e13843

[83] Adams V,Augstein A.Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility.J Cachexia Sarcopenia Muscle2022;13:1565-81 PMCID:PMC9178400

[84] Winzer EB,Langner E.Empagliflozin preserves skeletal muscle function in a HFpEF rat model.Int J Mol Sci2022;23:10989 PMCID:PMC9570453

[85] Quiriarte H,Stampley JE.Exercise therapy rescues skeletal muscle dysfunction and exercise intolerance in cardiometabolic HFpEF.JACC Basic Transl Sci2024;9:1409-25 PMCID:PMC11733766

[86] Zhang K,Wang B.FGF21 protects against HFpEF by improving cardiac mitochondrial bioenergetics in mice.Nat Commun2025;16:1661 PMCID:PMC11829982

[87] Wang X,Wang Y.Astragaloside IV alleviates inflammation and improves myocardial metabolism in heart failure mice with preserved ejection fraction.Front Pharmacol2024;15:1467132 PMCID:PMC11618538

[88] Winzer EB,Schauer A.Impact of different training modalities on molecular alterations in skeletal muscle of patients with heart failure with preserved ejection fraction: a substudy of the OptimEx trial.Circ Heart Fail2022;15:e009124

[89] Dong J,Feng Y.Exercise training alleviates myocardial injury in mice with heart failure with preserved ejection fraction via the TLR4-mediated necroptosis pathway.Int Immunopharmacol2026;176:116513

[90] Kolijn D,Tian Y.Empagliflozin improves endothelial and cardiomyocyte function in human heart failure with preserved ejection fraction via reduced pro-inflammatory-oxidative pathways and protein kinase Gα oxidation.Cardiovasc Res2021;117:495-507

[91] Qiu Z,Wang Z.Catestatin protects against diastolic dysfunction by attenuating mitochondrial reactive oxygen species generation.J Am Heart Assoc2023;12:e029470 PMCID:PMC10227223

[92] Deng Y,Li Q.Targeting mitochondria-inflammation circuit by β-hydroxybutyrate mitigates HFpEF.Circ Res2021;128:232-45

[93] Koay YC,Ng YH.The heart has intrinsic ketogenic capacity that mediates NAD⁺ therapy in HFpEF.Circ Res2025;136:1113-30

[94] Zhang X,Fu P.Dapagliflozin attenuates heart failure with preserved ejection fraction remodeling and dysfunction by elevating β-hydroxybutyrate-activated citrate synthase.J Cardiovasc Pharmacol2023;82:375-88

[95] Quan J,Liu L.The effect of long-term administration of green tea catechins on aging-related cardiac diastolic dysfunction and decline of troponin I.Genes Dis2025;12:101284 PMCID:PMC11699727

[96] Kitzman DW,Pandey A.A novel controlled metabolic accelerator for the treatment of obesity-related heart failure with preserved ejection fraction: rationale and design of the phase 2a HuMAIN trial.Eur J Heart Fail2024;26:2013-24 PMCID:PMC11704968

[97] Pandey A,Borlaug BA.Novel controlled metabolic accelerator for obesity-related HFpEF: the HuMAIN-HFpEF randomized clinical trial.JAMA Cardiol2025;10:609-16 PMCID:PMC11904796

[98] Schauer A,Vahle B.Mitochondrial targeting by elamipretide improves myocardial bioenergetics without translating into functional benefits in HFpEF.Int J Mol Sci2026;27:1060 PMCID:PMC12841679